Clinical Trials

Leukemia, Myeloid, Acute

NCT02728050 2023-07-05

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

MyeloidOther hematologic neoplasm

84 enrolled 28 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT05596968 2022-10-27

The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT

Unknown

37 enrolled

Leukemia, Myeloid, Acute

NCT05596981 2022-10-27

The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT

Unknown

60 enrolled

Leukemia, Myeloid, Acute

NCT04326439 2022-06-15

AflacLL1901 (CHOA-AML)

Phase 2 Terminated

8 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT04788420 2022-06-01

Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML

Completed

456 enrolled

Leukemia, Myeloid, Acute

NCT04752527 2021-11-15

Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features

Phase 2 Unknown

42 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01620216 2021-11-04

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Phase 2 Terminated

12 enrolled 12 charts

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02779283 2020-05-26

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

7 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02530476 2020-03-31

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

17 enrolled 14 charts

Leukemia, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03170895 2020-03-30

Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD

5 enrolled

Leukemia, Myeloid, Acute

NCT02196857 2020-01-14

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

16 enrolled 8 charts

Leukemia, Leukemia, Myeloid, Acute

NCT02474290 2019-08-26

Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML

Phase 2/3 Completed

202 enrolled

Leukemia, Myeloid, Acute

NCT02412475 2019-01-24

Epigenetic Reprogramming in Relapse AML

Phase 1 Terminated

3 enrolled

Leukemia, Myeloid, Acute

NCT01534260 2018-08-17

Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype

37 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT00908167 2018-01-12

Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

44 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT02270788 2017-10-03

Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

10 enrolled

Leukemia, Myeloid, Acute

NCT00943943 2017-03-29

Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

33 enrolled

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT01398501 2017-03-22

Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant

22 enrolled

Leukemia, Myeloid, Acute

NCT01254890 2016-05-06

Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome

MyeloidOther hematologic neoplasm

60 enrolled 5 charts

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00893373 2016-02-05

SORAML

276 enrolled

Leukemia, Myeloid, Acute

NCT00875745 2014-09-18

Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

MyeloidOther hematologic neoplasm

15 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

NCT01159301 2013-09-19

Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia

Phase 1 Terminated

44 enrolled

Congenital Abnormalities, Blast Crisis, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT00131989 2013-01-09

Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

LymphoidOther hematologic neoplasm

48 enrolled

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00373373 2009-08-19

Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML

200 enrolled